Abstract 180P
Background
HCC is a leading global cause of cancer mortality, particularly in the Asia-Pacific region (APAC). An understanding of RW tx patterns and outcomes in APAC may inform current disease management. Here we report tx patterns and survival outcomes in a RW population of pts from Taiwan and Singapore with intermediate/advanced HCC.
Methods
This secondary data study from the HCC Registry in Asia (NCT03233360) used third-party (IQVIA) de-identified pt-level data collected retrospectively and prospectively from electronic health records from Taiwan and Singapore, including for pts newly diagnosed with HCC from Jan 2013 to Dec 2019. Descriptive statistics were used to summarize tx patterns (sequence, frequency) and pt characteristics by country and BCLC staging B or C; the Kaplan-Meier method was used to estimate median overall survival (mOS).
Results
Pt characteristics by stage and country are in the table. In Singapore in pts with BCLC B (n = 26), TARE/Y90 was the most common 1st tx (50%) followed by resection (19.2%). In BCLC C pts (n = 22) systemic therapies were common (68.2%). In Taiwan, BCLC B pts (n = 51) were often treated with resection (43.1%) or TACE (31.4%); BCLC C pts (n = 46) were most often treated with systemic therapy (41.3%). mOS in BCLC B pts was 21 mo in Singapore and 25 mo in Taiwan. In BCLC C pts mOS was 4 mo in Singapore and 6 mo in Taiwan.
Conclusions
This study showed utilization patterns of available tx options in and characteristics of HCC pts in Singapore and Taiwan despite the limited sample size. HCC RW data from APAC are scarce. This registry’s data collection, still ongoing outside Taiwan and Singapore, provides useful insights into RW practice and outcomes and illustrates urgent need for new tx options for HCC. As new txs emerge such as atezolizumab + bevacizumab for 1st line tx of unresectable or metastatic HCC, future RW studies extending this work will help reveal their RW impact on pts Table: 180P
Pt characteristics, tx frequency and tx sequence in Singapore and Taiwan
BCLC stage | Singapore | Taiwan | ||
B | C | B | C | |
Pts, n | 26 | 22 | 51 | 46 |
Age, years, median (IQR) | 66.0 (62.8-70.6) | 64.0 (60.0-67.8) | 65.4 (57.1-73.1) | 63.1 (55.7-68.1) |
Male, n (%) | 24 (92.3) | 15 (68.2) | 42 (82.4) | 37 (80.4) |
Hepatitis B positive, n (%) | 8 (30.8) | 12 (54.5) | 30 (58.8) | 23 (50.0) |
Pts with subsequent tx, n | 8 | 6 | 3 | 10 |
Most common subsequent tx (%)a | Syst ther (50.0) | Syst ther (83.3) | LRT (66.7) | Syst ther (90.0) |
BCLC, Barcelona Clinic Liver Cancer; LRT, locoregional therapy; Syst ther, systemic therapy; TACE, transarterial chemoembolization; TARE/Y90, transarterial radioembolization with yttrium-90 a % calculated among all pts receiving a subsequent tx
.Clinical trial identification
NCT03233360.
Editorial acknowledgement
Medical writing assistance for this abstract was provided by Chris Lum, PhD of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
S.P. Choo: Honoraria (self), Advisory/Consultancy: eisai; Honoraria (self), Advisory/Consultancy: Bristol Myers Squibb; Speaker Bureau/Expert testimony: DKSH; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Ipsen. S.K. Mhatre: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech, Inc. A. Ferro: Full/Part-time employment: Genentech/Roche. R. Machado, D.H-C. Liu, N. Irahara: Full/Part-time employment: Roche. V.E. Gaillard: Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session